Current Colorectal Cancer Reports

, Volume 13, Issue 2, pp 126–135 | Cite as

Personalizing Locoregional Therapy for Patients with Metastatic Colorectal Cancer

  • Young Hong
  • Robert C. G. MartinIIEmail author
Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Personalized Medicine in Colorectal Cancer


Purpose of review

The management of metastatic colorectal liver disease has improved overall survival by multidisciplinary approach utilizing systemic treatment followed by local control of metastatic disease. There has been an evolution of local control therapy which has expanded the new armamentarium for treatment of resectable and unresectable liver disease. The review article will address the various types of locoregional therapy and various indications for its use.

Recent findings

The application of ablative therapies combined with resections has allowed single-stage resection for patients with bilobar disease with excellent safety and efficacy. In patients with unresectable colorectal metastasis to the liver, chemo- and radio-embolization have provided improved survival outcome compared to systemic chemotherapy alone.


Locoregional therapy for metastatic colorectal liver disease can improve outcome as an adjunctive role in combination with resection or as a sole therapy for patients with unresectable disease.


Metastatic colorectal cancer Locoregional therapy Ablation Irreversible electroporation Radioembolization Chemoembolization 


Compliance with Ethical Standards

Conflict of Interest

Young Hong and Robert C.G. Martin II declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Leporrier J et al. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Akgul O et al. Role of surgery in colorectal cancer liver metastases. World J Gastroenterol. 2014;20(20):6113–22.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Salek T et al. Combination of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience. J Clin Oncol. 2011;29(15_suppl):e14152.CrossRefGoogle Scholar
  4. 4.
    •• Xu W et al. Survival benefit and safety of the combinations of FOLFOXIRI +/− bevacizumab versus the combinations of FOLFIRI +/− bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. Onco Targets Ther. 2016;9:4833–42. Improved combination chemotherapy regimen can improve overall and progression free survival with acceptable toxicity and should be used in patients with metastatic colorectal cancer.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol. 2016;7(5):687–704.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Salek T et al. Combination of cetuximab and chemotherapy in the first-line treatment of metastatic colorectal cancer: Slovakian experience. J Clin Oncol. 2011;29(4_suppl):622.CrossRefGoogle Scholar
  7. 7.
    Pietrantonio F, et al. Perioperative triplet chemotherapy and cetuximab in patients with RAS wild type high recurrence risk or borderline resectable colorectal cancer liver metastases. Clin Color Cancer. 2016.Google Scholar
  8. 8.
    Nagashima M et al. Treatment of oxaliplatin-induced peripheral neuropathy with oxycodone and extension of FOLFOX in patients with advanced colorectal cancer. J Clin Oncol. 2011;29(15_suppl):e19534.CrossRefGoogle Scholar
  9. 9.
    Choti MA et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(6):759–66.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    House MG et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52. 752–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Andreou A et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg. 2013;257(6):1079–88.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Ward E et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.PubMedCrossRefGoogle Scholar
  13. 13.
    Barret M et al. Does nutritional status affect treatment tolerability and efficacy in metastatic colorectal cancer (mCRC) patients? Results of a prospective multicenter study. J Clin Oncol. 2011;29(15_suppl):e14018.CrossRefGoogle Scholar
  14. 14.
    • Fagard K et al. The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: a systematic review. J Geriatr Oncol. 2016;7(6):479–91. Frailty of the patient should be addressed as a potential impact on outcome in patients with resectable metastatic disease.PubMedCrossRefGoogle Scholar
  15. 15.
    Hemming AW et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237(5):686–91. discussion 691–3.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Bentrem DJ, Dematteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Annu Rev Med. 2005;56:139–56.PubMedCrossRefGoogle Scholar
  17. 17.
    Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13(1):51–64.PubMedCrossRefGoogle Scholar
  18. 18.
    Jawed I et al. Colorectal cancer survival gains and novel treatment regimens: a systematic review and analysis. JAMA Oncol. 2015;1(6):787–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Wong SL et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493–508.PubMedCrossRefGoogle Scholar
  20. 20.
    Fong Y et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Van Cutsem E et al. Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–16.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    National Comprehensive Cancer Network. Colon Cancer (Version 2.2016). February 4, 2017; Available from:
  24. 24.
    Bilchik AJ et al. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol. 2008;26(33):5320–1.PubMedCrossRefGoogle Scholar
  25. 25.
    Araujo R et al. Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer. Ann Surg Oncol. 2013;20(13):4312–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Jaeck D et al. A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg. 2004;240(6):1037–49. discussion 1049–51.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Jaeck D et al. One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am J Surg. 2003;185(3):221–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Abdalla EK et al. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford). 2013;15(2):119–30.CrossRefGoogle Scholar
  29. 29.
    Martin RC et al. Locoregional surgical and interventional therapies for advanced colorectal liver metastasis: expert consensus statement. HPB (Oxford). 2013;15(2):131–3.CrossRefGoogle Scholar
  30. 30.
    •• Philips P et al. Single-stage resection and microwave ablation for bilobar colorectal liver metastases. Br J Surg. 2016;103(8):1048–54. Single stage resection is safe and feasible for bilobar disease when combined with ablative therapy and minimize morbidity.PubMedCrossRefGoogle Scholar
  31. 31.
    Philips P, et al. Safety and advantages of combined resection and microwave ablation in patients with bilobar hepatic malignancies. Int J Hyperth. 2016;1–21.Google Scholar
  32. 32.
    Lim C et al. Primary tumor versus liver-first strategy in patients with stage IVA colorectal cancer: a propensity score analysis of long-term outcomes and recurrence pattern. Ann Surg Oncol. 2016;23(9):3024–32.PubMedCrossRefGoogle Scholar
  33. 33.
    Martin R et al. Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. J Am Coll Surg. 2003;197(2):233–41. discussion 241–2.PubMedCrossRefGoogle Scholar
  34. 34.
    Reddy SK et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14(12):3481–91.PubMedCrossRefGoogle Scholar
  35. 35.
    •• Gani F et al. Patterns of hepatic resections in North America: use of concurrent partial resections and ablations. HPB (Oxford). 2016;18(10):813–20. Combined partial wedge resection and ablative therapy had equivalent outcome as those with partial lobectomy in patients with metastatic colorectal cancer to the liver.CrossRefGoogle Scholar
  36. 36.
    Abbott DE et al. Cost-effectiveness of simultaneous resection and RFA versus 2-stage hepatectomy for bilobar colorectal liver metastases. J Surg Oncol. 2014;109(6):516–20.PubMedCrossRefGoogle Scholar
  37. 37.
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.PubMedCrossRefGoogle Scholar
  38. 38.
    Egger ME et al. Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. J Am Coll Surg. 2013;216(4):845–56.PubMedCrossRefGoogle Scholar
  39. 39.
    Akinwande O et al. Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy. J Surg Oncol. 2016;113(4):443–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Nielsen K et al. The use of PET-MRI in the follow-up after radiofrequency- and microwave ablation of colorectal liver metastases. BMC Med Imaging. 2014;14:27.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Cornelis F et al. 18F-FDG PET/CT is an immediate imaging biomarker of treatment success after liver metastasis ablation. J Nucl Med. 2016;57(7):1052–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Ahmed M et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. J Vasc Interv Radiol. 2014;25(11):1691–705. e4.PubMedCrossRefGoogle Scholar
  43. 43.
    Kang TW et al. Terminology and reporting criteria for radiofrequency ablation of tumors in the scientific literature: systematic review of compliance with reporting standards. Korean J Radiol. 2014;15(1):95–107.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    •• North DA et al. Microwave ablation for hepatic malignancies: a call for standard reporting and outcomes. Am J Surg. 2014;208(2):284–94. There are wide variation in reporting of outcomes after microwave ablation which prevents accurate comparison of studies that are published. Consistent terminology will help communicate effectively across various centers that perform ablative therapy.PubMedCrossRefGoogle Scholar
  45. 45.
    Hompes D, Prevoo W, Ruers T. Radiofrequency ablation as a treatment tool for liver metastases of colorectal origin. Cancer Imaging. 2011;11:23–30.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Hur H et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197(6):728–36.PubMedCrossRefGoogle Scholar
  47. 47.
    Nielsen K et al. Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg. 2013;37(6):1340–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Sucandy I et al. Long-term survival outcomes of patients undergoing treatment with radiofrequency ablation for hepatocellular carcinoma and metastatic colorectal cancer liver tumors. HPB (Oxford). 2016;18(9):756–63.CrossRefGoogle Scholar
  49. 49.
    Siperstein AE et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246(4):559–65. discussion 565–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Kingham TP et al. Patterns of recurrence after ablation of colorectal cancer liver metastases. Ann Surg Oncol. 2012;19(3):834–41.PubMedCrossRefGoogle Scholar
  51. 51.
    Stang A et al. Impact of systemic therapy and recurrence pattern on survival outcome after radiofrequency ablation for colorectal liver metastases. J Cancer. 2016;7(14):1939–49.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Ruers T, Punt C, Coevorden F, Pierie JP, Rinkes I, Ledermann J, Poston G, Bechstein W, Lentz MA, Mauer M, Cutsem E, Lutz M, Nordlinger B. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). In 2015 ASCO Annual Meeting. 2015.Google Scholar
  53. 53.
    Reuter NP et al. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg. 2009;13(3):486–91.PubMedCrossRefGoogle Scholar
  54. 54.
    Lu DS et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol. 2003;14(10):1267–74.PubMedCrossRefGoogle Scholar
  55. 55.
    van Duijnhoven FH et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol. 2006;13(5):651–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Stang A et al. Selection criteria for radiofrequency ablation for colorectal liver metastases in the era of effective systemic therapy: a clinical score based proposal. BMC Cancer. 2014;14:500.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Simon CJ, Dupuy DE, Mayo-Smith WW. Microwave ablation: principles and applications. Radiographics. 2005;25 Suppl 1:S69–83.PubMedCrossRefGoogle Scholar
  58. 58.
    Chetboun M et al. Complete necrosis after microwave thermosphere ablation of liver metastases from colorectal cancer, histological proof of efficacy. J Surg Oncol. 2016;113(7):843–4.PubMedCrossRefGoogle Scholar
  59. 59.
    Martin RC, Scoggins CR, McMasters KM. Microwave hepatic ablation: initial experience of safety and efficacy. J Surg Oncol. 2007;96(6):481–6.PubMedCrossRefGoogle Scholar
  60. 60.
    Pillai K et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore). 2015;94(9):e580.CrossRefGoogle Scholar
  61. 61.
    Ringe KI et al. Experimental evaluation of the heat sink effect in hepatic microwave ablation. PLoS One. 2015;10(7):e0134301.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Martin RC, O.C.R. Microwave ablation and irreversible electroporation, in Blumgart’s surgery of the liver, pancreas and biliary tract, W.R. Jarnagin, Editor. 2016. Elsevier Health Sciences.Google Scholar
  63. 63.
    Groeschl RT et al. Recurrence after microwave ablation of liver malignancies: a single institution experience. HPB (Oxford). 2013;15(5):365–71.CrossRefGoogle Scholar
  64. 64.
    Wada Y et al. Efficacy of surgical treatment using microwave coagulo-necrotic therapy for unresectable multiple colorectal liver metastases. Onco Targets Ther. 2016;9:937–43.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Karanicolas PJ et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg. 2013;148(7):597–601.PubMedPubMedCentralCrossRefGoogle Scholar
  66. 66.
    Leung U et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg. 2015;102(1):85–91.PubMedCrossRefGoogle Scholar
  67. 67.
    •• Correa-Gallego C et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol. 2014;21(13):4278–83. Comparision of microwave ablation versus radiofrequency ablation demonstrated a decreased local recurrence.Google Scholar
  68. 68.
    Li W et al. Microwave ablation as palliative treatment of locally recurrent colorectal cancer. Indian J Cancer. 2015;52 Suppl 2:e61–3.PubMedGoogle Scholar
  69. 69.
    Francone E, et al. Precoagulation-assisted parenchyma-sparing laparoscopic liver surgery: rationale and surgical technique. Surg Endosc. 2016.Google Scholar
  70. 70.
    •• Groeschl RT et al. Microwave ablation for hepatic malignancies: a multiinstitutional analysis. Ann Surg. 2014;259(6):1195–200. Local recurrence of a lesion after microwave ablation was correlated with size of the tumor. Tumor greater than 3cm was associated with increased risk of local recurrence after microwave ablation.PubMedCrossRefGoogle Scholar
  71. 71.
    Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17(1):171–8.PubMedCrossRefGoogle Scholar
  72. 72.
    van Tilborg AA et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc Intervent Radiol. 2016;39(10):1438–46.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Al-Sakere B et al. Tumor ablation with irreversible electroporation. PLoS One. 2007;2(11):e1135.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Kwon D et al. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery. 2014;156(4):910–20.PubMedCrossRefGoogle Scholar
  75. 75.
    Martin 2nd RC et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262(3):486–94. discussion 492–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Bhutiani N et al. Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma. J Surg Oncol. 2016;114(2):181–6.PubMedCrossRefGoogle Scholar
  77. 77.
    •• Bhutiani N et al. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford). 2016;18(7):593–9. Irreversible electroporation can be utilized in patients with hepatocellular carcinoma as an additional non-thermal treatment option.CrossRefGoogle Scholar
  78. 78.
    Bond L, et al. Intra-operative navigation of a 3-dimensional needle localization system for precision of irreversible electroporation needles in locally advanced pancreatic cancer. Eur J Surg Oncol. 2016.Google Scholar
  79. 79.
    Martin 2nd RC et al. Irreversible electroporation in locally advanced pancreatic cancer: a call for standardization of energy delivery. J Surg Oncol. 2016;114(7):865–71.PubMedCrossRefGoogle Scholar
  80. 80.
    Collins JM. Pharmacologic rationale for regional drug delivery. J Clin Oncol. 1984;2(5):498–504.PubMedCrossRefGoogle Scholar
  81. 81.
    Zorzi D et al. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007;94(3):274–86.PubMedCrossRefGoogle Scholar
  82. 82.
    Dhir M, et al. Robotic-assisted placement of an hepatic artery infusion pump and catheter for regional chemotherapy of the liver. Ann Surg Oncol. 2016.Google Scholar
  83. 83.
    Kemeny NE et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395–403.PubMedCrossRefGoogle Scholar
  84. 84.
    Levi FA et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27(2):267–74.PubMedCrossRefGoogle Scholar
  85. 85.
    Mocellin S et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25(35):5649–54.PubMedCrossRefGoogle Scholar
  86. 86.
    Kemeny NE et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Goi T et al. Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer. World J Surg Oncol. 2015;13:296.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    Cercek A et al. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol. 2016;114(6):655–63.PubMedCrossRefGoogle Scholar
  89. 89.
    Kemeny NE et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016;113(5):477–84.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Onaitis M et al. Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases. Ann Surg. 2003;237(6):782–8. discussion 788–9.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Martin RC, Edwards MJ, McMasters KM. Morbidity of adjuvant hepatic arterial infusion pump chemotherapy in the management of colorectal cancer metastatic to the liver. Am J Surg. 2004;188(6):714–21.PubMedCrossRefGoogle Scholar
  92. 92.
    Bhutiani N, Martin 2nd RC. Transarterial therapy for colorectal liver metastases. Surg Clin N Am. 2016;96(2):369–91.PubMedCrossRefGoogle Scholar
  93. 93.
    Gruber-Rouh T et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer. 2014;134(5):1225–31.PubMedCrossRefGoogle Scholar
  94. 94.
    Ceelen W et al. Initial experience with the use of preoperative transarterial chemoembolization in the treatment of liver metastasis. Acta Chir Belg. 1996;96(1):37–40.PubMedGoogle Scholar
  95. 95.
    Leichman CG et al. Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: a Southwest Oncology Group pilot trial. Cancer. 1999;86(5):775–81.PubMedCrossRefGoogle Scholar
  96. 96.
    Muller H et al. Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases. Eur J Surg Oncol. 2001;27(7):652–61.PubMedCrossRefGoogle Scholar
  97. 97.
    Salman HS et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer. 2002;2(3):173–9.PubMedCrossRefGoogle Scholar
  98. 98.
    Albert M et al. Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer. 2011;117(2):343–52.PubMedCrossRefGoogle Scholar
  99. 99.
    Lewis AL et al. Feasibility, safety and pharmacokinetic study of hepatic administration of drug-eluting beads loaded with irinotecan (DEBIRI) followed by intravenous administration of irinotecan in a porcine model. J Mater Sci Mater Med. 2013;24(1):115–27.PubMedCrossRefGoogle Scholar
  100. 100.
    •• Jones RP, et al. PARAGON II—a single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer. Eur J Surg Oncol. 2016. Single DEBIRI infusion had similar safety and efficacy as traditional systemic chemotherapy for resectable metastatic colorectal disease of the liver.Google Scholar
  101. 101.
    Bhutiani N, Akinwande O, Martin 2nd RC. Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. World J Surg. 2016;40(5):1178–90.PubMedCrossRefGoogle Scholar
  102. 102.
    Martin 2nd RC et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg. 2012;16(8):1531–8.PubMedCrossRefGoogle Scholar
  103. 103.
    •• Martin RC et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58. Combination of systemic chemotherapy FOLFOX plus bevacizumab and DEBIRI demonstrated improved overall and progression free survival in patients with unresectable metastatic colorectable liver disease.PubMedCrossRefGoogle Scholar
  104. 104.
    Fiorentini G et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.PubMedGoogle Scholar
  105. 105.
    Fiorentini G et al. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrointest Oncol. 2015;7(6):47–54.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Bilhim T, Pisco JM. The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in the management of the post-embolization symptoms after uterine artery embolization. Pharmaceuticals (Basel). 2010;3(6):1729–38.CrossRefGoogle Scholar
  107. 107.
    Lencioni R et al. Transarterial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol. 2014;25(3):365–9.PubMedCrossRefGoogle Scholar
  108. 108.
    Jones RP et al. Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction: a case–control series. HPB (Oxford). 2013;15(1):71–7.CrossRefGoogle Scholar
  109. 109.
    Mulcahy MF et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115(9):1849–58.PubMedCrossRefGoogle Scholar
  110. 110.
    van Hazel GA et al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol. 2009;27(25):4089–95.PubMedCrossRefGoogle Scholar
  111. 111.
    Coldwell D et al. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol. 2011;34(3):337–41.PubMedCrossRefGoogle Scholar
  112. 112.
    Hong K et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009;20(3):360–7.PubMedCrossRefGoogle Scholar
  113. 113.
    van Hazel GA et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31.PubMedCrossRefGoogle Scholar
  114. 114.
    Dutton SJ et al. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional selective internal radiation therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14:497.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Townsend AR et al. Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treat Rev. 2016;50:148–54.PubMedCrossRefGoogle Scholar
  116. 116.
    Malik U, Mohiuddin M. External-beam radiotherapy in the management of liver metastases. Semin Oncol. 2002;29(2):196–201.PubMedCrossRefGoogle Scholar
  117. 117.
    Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol. 2011;21(4):256–63.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Hoyer M et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–30.PubMedCrossRefGoogle Scholar
  119. 119.
    Blomgren H et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34(6):861–70.PubMedCrossRefGoogle Scholar
  120. 120.
    Wulf J et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45(7):838–47.PubMedCrossRefGoogle Scholar
  121. 121.
    Katz AW et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67(3):793–8.PubMedCrossRefGoogle Scholar
  122. 122.
    Yamashita H et al. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors in 130 Japanese patients. Radiat Oncol. 2014;9:112.PubMedPubMedCentralCrossRefGoogle Scholar
  123. 123.
    Aitken KL, Hawkins MA. Stereotactic body radiotherapy for liver metastases. Clin Oncol (R Coll Radiol). 2015;27(5):307–15.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Division of Surgical Oncology, Department of SurgeryUniversity of LouisvilleLouisvilleUSA

Personalised recommendations